AI Article Synopsis
- This study aimed to estimate the incidence and impact of rheumatoid arthritis (RA) in Taiwan, focusing on life expectancy and healthcare costs post-2003 when biologic treatments were introduced.
- Researchers analyzed health claims data from 1999-2016, identifying 29,352 new RA cases and comparing the life expectancy and healthcare costs of RA patients against matched referents.
- Results showed a decrease in RA incidence, mean life expectancy after diagnosis was 26.3 years with an average lifetime cost of $72,953, and women with RA faced greater loss of life expectancy compared to men, though annual healthcare costs were similar for both sexes.
Article Abstract
Objective: This study was undertaken to estimate the cumulative incidence rate of rheumatoid arthritis (RA) in the Taiwanese population ages 16-84 years, and life expectancy, loss of life expectancy, and lifetime health care expenditures for incident RA in Taiwan after 2003, when biologics began to be prescribed.
Methods: We obtained all claims data for the period 1999 to 2016 from the National Health Insurance program of Taiwan, and validated the data against the Catastrophic Illness Registry to establish the study cohort. We estimated the survival function for RA and extrapolated to lifetime using a rolling-over algorithm. For every RA case, we simulated sex-, age-, and calendar year-matched referents from vital statistics and estimated their life expectancy. The difference between the life expectancy of the referent and the life expectancy of the RA patient was the loss of life expectancy for the RA patient. Average monthly health care expenditures were multiplied by the corresponding survival rates and summed up throughout the lifetime to calculate the lifetime health care expenditures.
Results: A total of 29,352 new RA cases were identified during 2003-2016. There was a decreasing trend in cumulative incidence rate in those ages 16-84 for both sexes. Mean life expectancy after diagnosis of RA was 26.3 years, and mean lifetime cost was $72,953. RA patients had a mean loss of life expectancy of 4.97 years. Women with RA survived 1-2 years longer than men with RA of the same age, which resulted in higher lifetime expenditures for the former. Since the life expectancy for women in Taiwan was 6-7 years higher than that for men, the loss of life expectancy for women with RA was higher than that for men with RA. Annual health care expenditures were similar for both sexes.
Conclusion: Our findings indicate that since biologics became available, RA patients have lived longer and had higher lifetime expenditures, which should be monitored and evaluated for cost-effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247851 | PMC |
| http://dx.doi.org/10.1002/art.41597 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recruitment, follow-up and survival in an 11-country cohort study of patients at the end of life and their relatives.
PLoS One
January 2025
Institute for Palliative Care, Region Skåne and Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Background: Large, international cohort studies generate high-level evidence, but are resource intense. In end-of-life care such studies are scarce. Hence, planning for future studies in terms of data on screening, recruitment, retention and survival remains a challenge.
View Article and Find Full Text PDFAddressing challenges in the implementation of precision oncology: An in-depth examination of limitations and disparities in the treatment of non-small cell lung cancer in the Brazilian public healthcare system (SUS).
Glob Public Health
December 2025
Department of Oncology and Hematology, ABC Medical School, Sao Paulo, Brazil.
Precision oncology (PO) has significantly advanced lung cancer treatment by enabling personalised therapy based on genetic mutations. However, equitable access to molecular testing and targeted therapies remains a challenge, particularly in resource-limited settings such as the Brazilian Public Health System (SUS). To identify the challenges faced by SUS in caring for patients with non-small cell lung cancer (NSCLC) in terms of access to Precision Oncology.
View Article and Find Full Text PDFIncrease in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study.
Rheumatol Int
January 2025
Department of Rheumatology, AIIMS, New Delhi, India.
Background: Psoriatic arthritis (PsA) significantly contributes to increased morbidity, reduced life expectancy, and higher healthcare costs due to the burden of comorbidities. This study assessed the prevalence of comorbidities in PsA patients in India and explored the influence of age and disease duration on these comorbidities.
Methods: The prospective, multicenter observational study was conducted across seven centers in India, utilizing data from the Indian Rheumatology Association.
Background: Down Syndrome (DS) is the most common genetic form of intellectual disability. In recent years, there has been a significant increase in the life expectancy of individuals with DS, currently reaching the age of 60 or over. However, it has been observed that as of age 40, these individuals experience higher risk of developing dementia, and almost all of them exhibit histopathological characteristics of Alzheimer's disease (AD) in their brains.
View Article and Find Full Text PDFBackground: Older adults with type 2 diabetes (T2D) are more likely to develop Alzheimer's disease (AD) due to impaired brain metabolism. Although the underlying mechanisms of this relationship are largely unknown, lower levels of brain-derived neurotrophic factor (BDNF) -which promotes hippocampal neurogenesis in adulthood- and atrophy of the hippocampus are evident in patients with T2D and dementia, possibly linking the two conditions. The hippocampus is comprised of multiple subfields, each with their respective functions, cellular composition, and age-related sensitivity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!